R. O’Donnell

发表

Phosphatase inhibition augments anti-CD22-mediated signaling and cytotoxicity in non-hodgkin's lymphoma cells.

R. O’Donnell, D. Pearson, H. McKnight, 2009, Leukemia research.

CD22 antigen is broadly expressed on lung cancer cells and is a target for antibody-based therapy.

D. Gandara, R. O’Donnell, D. Pearson, 2012, Cancer research.

Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment.

D. Gandara, P. Lara, F. Meyers, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The HB22.7 Anti-CD22 monoclonal antibody enhances bortezomib-mediated lymphomacidal activity in a sequence dependent manner

R. O’Donnell, H. McKnight, J. Tuscano, 2011, Journal of hematology & oncology.

Development and characterization of CD22-targeted pegylated-liposomal doxorubicin (IL-PLD)

R. O’Donnell, J. Tuscano, W. Zamboni, 2009, Investigational New Drugs.

A clinical trial of radioimmunotherapy with 67Cu-2IT-BAT-Lym-1 for non-Hodgkin's lymphoma.

S Shen, G L DeNardo, K. Lamborn, 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Antibody responses to macrocycles in lymphoma.

G. Denardo, S. Denardo, C. Meares, 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Maximum tolerated dose of 67Cu-2IT-BAT-LYM-1 for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: a pilot study.

G. Denardo, S. Denardo, S. Shen, 1998, Anticancer research.

Prediction of myelotoxicity using radiation doses to marrow from body, blood and marrow sources.

G. Denardo, S. Denardo, S. Shen, 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Efficacy of a CD22-targeted antibody-saporin conjugate in a xenograft model of precursor-B cell acute lymphoblastic leukemia.

N. Satake, R. O’Donnell, J. Tuscano, 2013, Leukemia research.

Efficacy and toxicity of a CD22-targeted antibody-saporin conjugate in a xenograft model of non-Hodgkin’s lymphoma

R. O’Donnell, J. Tuscano, J. Kato, 2012, Oncoimmunology.

Comparison of normal tissue pharmacokinetics with 111In/90Y monoclonal antibody m170 for breast and prostate cancer.

G. Denardo, S. Denardo, J. Lehmann, 2006, International journal of radiation oncology, biology, physics.

Radiation dosimetry for 90Y-2IT-BAD-Lym-1 extrapolated from pharmacokinetics using 111In-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma.

G. Denardo, S. Denardo, S. Shen, 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Enhanced therapeutic index of radioimmunotherapy (RIT) in prostate cancer patients: comparison of radiation dosimetry for 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-peptide versus 2IT-DOTA monoclonal antibody linkage for RIT.

K. Lamborn, G. Denardo, S. Denardo, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

The Bs20x22 anti-CD20-CD22 bispecific antibody has more lymphomacidal activity than do the parent antibodies alone

R. O’Donnell, J. Tuscano, J. Kato, 2011, Cancer Immunology, Immunotherapy.

Optimized conditions for chelation of yttrium-90-DOTA immunoconjugates.

G. Denardo, S. Denardo, D. Kukis, 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Disulfide cross-linked micelles for the targeted delivery of vincristine to B-cell lymphoma.

K. Lam, K. Xiao, Juntao Luo, 2012, Molecular pharmaceutics.

A phase I trial of escalating doses of cixutumumab (IMC-A12) and sorafenib in the treatment of advanced hepatocellular carcinoma

Y. Yen, D. Gandara, H. Lenz, 2018, Cancer Chemotherapy and Pharmacology.

Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and 90yttrium‐DOTA‐peptide‐ChL6

K. Lamborn, G. Denardo, S. Denardo, 2002, The Prostate.

SPLENIC VOLUME CHANGE AND THERAPUETIC RESPONSE IN PATIENTS TREATED WITH RADIOMMUNOCONJUGATES

G. Denardo, S. Denardo, S. Shen, 2005 .

Efficacy of Combined Histone Deacetylase and Checkpoint Kinase Inhibition in a Preclinical Model of Human Burkitt Lymphoma

R. O’Donnell, J. Tuscano, G. Barisone, 2015, Molecular medicine.

Histone deacetylase inhibition enhances the lymphomacidal activity of the anti-CD22 monoclonal antibody HB22.7.

R. O’Donnell, J. Tuscano, G. Barisone, 2014, Leukemia research.

Strategies for developing effective radioimmunotherapy for solid tumors.

G. Denardo, S. Denardo, S. Shen, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Targeting CD22 in B-cell Malignancies: Current Status and Clinical Outlook

R. O’Donnell, J. Tuscano, Loretta Sullivan-Chang, 2013, BioDrugs.

Neovascular targeting with cyclic RGD peptide (cRGDf-ACHA) to enhance delivery of radioimmunotherapy.

K. Lamborn, G. Denardo, S. Denardo, 2000, Cancer biotherapy & radiopharmaceuticals.

Nuclear localizing sequences: an innovative way to improve targeted radiotherapy.

R. O’Donnell, R. O'donnell, 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

An Evaluation of Barriers to Accrual in the Era of Legislation Requiring Insurance Coverage of Cancer Clinical Trial Costs in California

L. Beckett, D. Gandara, H. Chew, 2004, Cancer journal.

Enhancement of the Therapeutic Index: From Nonmyeloablative and Myeloablative toward Pretargeted Radioimmunotherapy for Metastatic Prostate Cancer

J. Gregg, G. Denardo, S. Denardo, 2005, Clinical Cancer Research.

Enhancement of theTherapeutic Index : FromNonmyeloablative andMyeloablative toward Pretargeted Radioimmunotherapy forMetastatic Prostate Cancer

G. Denardo, S. Denardo, H. Albrecht, 2005 .

Preclinical evaluation of chimeric L6 antibody for the treatment of Kaposi's sarcoma with radioimmunotherapy.

L. Howell, G. Denardo, S. Denardo, 1999, Cancer biotherapy & radiopharmaceuticals.

Radioimmunotherapy with 111in/90y-2it-BAD-m170 for metastatic prostate cancer

G. Denardo, S. Denardo, S. Shen, 2001 .

Radioimmunotherapy with (111)In/(90)Y-2IT-BAD-m170 for metastatic prostate cancer.

F. Meyers, G. Denardo, S. Denardo, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Transfer of copper from a chelated 67Cu-antibody conjugate to ceruloplasmin in lymphoma patients.

G. Denardo, S. Denardo, S. Shen, 1999, Nuclear medicine and biology.

67Copper-2-iminothiolane-6-[p-(bromoacetamido)benzyl-TETA-Lym-1 for radioimmunotherapy of non-Hodgkin's lymphoma.

K. Lamborn, G. Denardo, S. Denardo, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Dosimetry-based therapy in metastatic breast cancer patients using 90Y monoclonal antibody 170H.82 with autologous stem cell support and cyclosporin A.

G. Denardo, S. Denardo, S. Shen, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Concentration in Blood and Body Practical Determination of Patient-Specific Marrow Dose Using Radioactivity

G. Denardo, S. Denardo, S. Shen, 2006 .

Characterization of canine neutrophil granules

B. Andersen, R. O’Donnell, R. O'donnell, 1982, Infection and immunity.

Enhancement of 67Cu‐2IT‐BAT‐LYM‐1 therapy in mice with human burkitt's lymphoma (Raji) using interleukin‐2

K. Lamborn, G. Denardo, S. Denardo, 1997, Cancer.

Combined modality radioimmunotherapy (RIT) in metastatic prostate (PC) and breast cancer (BC) using paclitaxel (PT) and a MUC-1 monoclonal antibody, m170, linked to yttrium-90 (Y-90): A phase I trial.

G. Denardo, S. Denardo, P. Lara, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Metabolite production in patients with lymphoma after radiometal-labeled antibody administration.

G. Denardo, S. Denardo, S. Shen, 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Implementation of timeline reforms speeds initiation of National Cancer Institute-sponsored trials.

J. Buckner, E. Korn, G. Hortobagyi, 2013, Journal of the National Cancer Institute.

A phase I study of 90Y-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma.

G. Denardo, S. Denardo, S. Shen, 2000, Anticancer research.

Practical determination of patient-specific marrow dose using radioactivity concentration in blood and body.

G. Denardo, S. Denardo, S. Shen, 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Imaging and Pharmacokinetics of 64Cu-DOTA-HB22.7 Administered by Intravenous, Intraperitoneal, or Subcutaneous Injection to Mice Bearing Non-Hodgkin’s Lymphoma Xenografts

C. Abbey, J. Sutcliffe, D. Kukis, 2009, Molecular Imaging and Biology.

Peripheral blood stem cell mobilization for hematopoietic support of radioimmunotherapy in patients with breast carcinoma

G. Denardo, S. Denardo, R. O’Donnell, 1997, Cancer.

A phase I trial of cixutumumab (C) (IMC-A12) and sorafenib (S) for treatment of advanced hepatocellular carcinoma (HCC).

Y. Yen, D. Gandara, H. Lenz, 2014 .

A phase II study of bortezomib in combination with pegylated liposomal doxorubicin for acute myeloid leukemia

R. O’Donnell, J. Tuscano, T. Wun, 2019, American journal of hematology.

Radioimmunotherapy for advanced breast cancer using I-131-ChL6 antibody.

K. Lamborn, G. Denardo, S. Denardo, 1997, Anticancer research.

Impact of splenomegaly on therapeutic response and I‐131‐LYM‐1 dosimetry in patients with B‐lymphocytic malignancies

G. Denardo, S. Denardo, S. Shen, 1997, Cancer.

Efficacy and toxicity of radioimmunotherapy with 90Y‐DOTA‐peptide‐ChL6 for PC3‐tumored mice

K. Lamborn, G. Denardo, S. Denardo, 2000, The Prostate.

Stability of monoclonal antibodies, Lym-1 and ChL6, and 2IT-BAD-Lym-1 immunoconjugate with ultra freezer storage.

G. Denardo, S. Denardo, S. Shen, 1999, Cancer biotherapy & radiopharmaceuticals.

A preliminary cell kinetics model of thrombocytopenia after radioimmunotherapy.

T. Jones, G. Denardo, S. Denardo, 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Effects of radiolysis on yttrium-90-labeled Lym-1 antibody preparations.

S. Denardo, R. O’Donnell, Q. Salako, 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Impact of interpatient pharmacokinetic variability on design considerations for therapy with radiolabeled MAbs.

G. Denardo, S. Denardo, S. Shen, 2003, Cancer biotherapy & radiopharmaceuticals.

Early diagnosis and successful treatment of a patient with transfusion‐associated GVHD with autologous peripheral blood progenitor cell transplantation

P. Holland, R. O’Donnell, J. Tuscano, 2002, Transfusion.

Potential use of amino acid cocktails to reduce renal tubular reabsorption of radioconjugates.

G. Denardo, S. Denardo, R. O’Donnell, 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Dose, timing, schedule, and the choice of targeted epitope alter the efficacy of anti-CD22 immunotherapy in mice bearing human lymphoma xenografts

R. O’Donnell, D. Pearson, H. McKnight, 2009, Cancer Immunology, Immunotherapy.

Treatment of refractory large granular lymphocytic leukemia with 2‐chlorodeoxyadenosine

M. Edelman, R. O’Donnell, Ivan Meadows, 1997, American journal of hematology.

Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in lymphoma xenografts.

K. Lamborn, G. Denardo, L. Miers, 2003, Blood.

Canine neutrophil plasma membrane markers.

B. Andersen, R. O’Donnell, R. O'donnell, 1985, Biochimica et biophysica acta.